Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Recruiting

Phase 2

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06108232

Conditions

Follicular Lymphoma

Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Obinutuzumab

CC-99282

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-05. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-04-27.